Articles

What do we still need to know about the treatment of RCC?

BJMO - , issue ,

L. Albiges

The introduction of immune checkpoint inhibitors dramatically changed the treatment paradigm of patients with advanced RCC. In her lecture, Dr. Laurence Albiges gave an overview of real-life data with nivolumab and gave her insights on how the first-line treatment landscape of patients with advanced RCC will evolve in the years to come.

Read more

What do we still need to know about the treatment of RCC?

BJMO - volume 12, issue 10, march 2018

L. Albiges

The introduction of immune checkpoint inhibitors dramatically changed the treatment paradigm of patients with advanced RCC. In her lecture, Dr. Laurence Albiges gave an overview of real-life data with nivolumab and gave her insights on how the first-line treatment landscape of patients with advanced RCC will evolve in the years to come.

Read more